Skip to main content
Top
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Short report

Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha

Authors: Lingli Yang, Tomoko Kiyohara, Tatsuo Kanda, Fumio Imazeki, Keiichi Fujiwara, Verena Gauss-Müller, Koji Ishii, Takaji Wakita, Osamu Yokosuka

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Hepatitis A virus (HAV) causes acute hepatitis and sometimes leads to fulminant hepatitis. Amantadine is a tricyclic symmetric amine that inhibits the replication of many DNA and RNA viruses. Amantadine was reported to suppress HAV replication, and the efficacy of amantadine was exhibited in its inhibition of the internal ribosomal entry site (IRES) activities of HAV. Interferon (IFN) also has an antiviral effect through the induction of IFN stimulated genes (ISG) and the degradation of viral RNA. To explore the mechanism of the suppression of HAV replication, we examined the effects of the combination of amantadine and IFN-alpha on HAV IRES-mediated translation, HAV replicon replication in human hepatoma cell lines, and HAV KRM003 genotype IIIB strain replication in African green monkey kidney cell GL37. IFN-alpha seems to have no additive effect on HAV IRES-mediated translation inhibition by amantadine. However, suppressions of HAV replicon and HAV replication were stronger with the combination than with amantadine alone. In conclusion, amantadine, in combination of IFN-alpha, might have a beneficial effect in some patients with acute hepatitis A.
Appendix
Available only for authorised users
Literature
1.
go back to reference FitzSimons D, Hendrickx G, Vorsters A, Damme PV: Hepatitis A and E: update on prevention and epidemiology. Vaccine 2010, 28: 583-588. 10.1016/j.vaccine.2009.10.136PubMedCrossRef FitzSimons D, Hendrickx G, Vorsters A, Damme PV: Hepatitis A and E: update on prevention and epidemiology. Vaccine 2010, 28: 583-588. 10.1016/j.vaccine.2009.10.136PubMedCrossRef
2.
go back to reference Kanda T, Yokosuka O, Imazeki F, Fujiwara K, Nagao K, Saisho H: Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochem Biophys Res Commun 2005, 331: 621-629. 10.1016/j.bbrc.2005.03.212PubMedCrossRef Kanda T, Yokosuka O, Imazeki F, Fujiwara K, Nagao K, Saisho H: Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochem Biophys Res Commun 2005, 331: 621-629. 10.1016/j.bbrc.2005.03.212PubMedCrossRef
3.
go back to reference Widell A, Hansson BG, Oberg B, Nordenfelt E: Influence of twenty potentially antiviral substances on in vitro multiplication of hepatitis A virus. Antiviral Res 1986, 6: 103-112. 10.1016/0166-3542(86)90030-6PubMedCrossRef Widell A, Hansson BG, Oberg B, Nordenfelt E: Influence of twenty potentially antiviral substances on in vitro multiplication of hepatitis A virus. Antiviral Res 1986, 6: 103-112. 10.1016/0166-3542(86)90030-6PubMedCrossRef
4.
go back to reference Kanda T, Zhang B, Kusov Y, Yokosuka O, Gauss-Müller V: Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site. Biochem Biophys Res Commun 2005, 330: 1217-1223. 10.1016/j.bbrc.2005.03.105PubMedCrossRef Kanda T, Zhang B, Kusov Y, Yokosuka O, Gauss-Müller V: Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site. Biochem Biophys Res Commun 2005, 330: 1217-1223. 10.1016/j.bbrc.2005.03.105PubMedCrossRef
5.
go back to reference Kanda T, Imazeki F, Nakamoto S, Okitsu K, Yokosuka O: Internal ribosomal entry-site activities of clinical isolates-derived hepatitis A virus and inhibitory effects of amantadine. Hepatol Res 2010, 40: 415-423. 10.1111/j.1872-034X.2010.00617.xPubMedCrossRef Kanda T, Imazeki F, Nakamoto S, Okitsu K, Yokosuka O: Internal ribosomal entry-site activities of clinical isolates-derived hepatitis A virus and inhibitory effects of amantadine. Hepatol Res 2010, 40: 415-423. 10.1111/j.1872-034X.2010.00617.xPubMedCrossRef
6.
go back to reference Crance JM, Biziagos E, Passagot J, van Cuyck-Gandre H, Deloince R: Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J Med Virol 1990, 31: 155-160. 10.1002/jmv.1890310214PubMedCrossRef Crance JM, Biziagos E, Passagot J, van Cuyck-Gandre H, Deloince R: Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J Med Virol 1990, 31: 155-160. 10.1002/jmv.1890310214PubMedCrossRef
7.
go back to reference Chen Y, Zeng S, Hsu JTA, Horng J, Yang H, Shih S, Chu Y, Wu T: Amantadine as a regulator of internal ribosome entry site. Acta Pharmacol Sin 2008, 29: 1327-1333. 10.1111/j.1745-7254.2008.00876.xPubMedCrossRef Chen Y, Zeng S, Hsu JTA, Horng J, Yang H, Shih S, Chu Y, Wu T: Amantadine as a regulator of internal ribosome entry site. Acta Pharmacol Sin 2008, 29: 1327-1333. 10.1111/j.1745-7254.2008.00876.xPubMedCrossRef
8.
go back to reference El-Sabbagh OI, Rady HM: Synthesis of new acridines and hydrazones derived from cyclic b-diketone for cytotoxic and antiviral evaluation. Eur J Med Chem 2009, 44: 3680-3686. 10.1016/j.ejmech.2009.04.001PubMedCrossRef El-Sabbagh OI, Rady HM: Synthesis of new acridines and hydrazones derived from cyclic b-diketone for cytotoxic and antiviral evaluation. Eur J Med Chem 2009, 44: 3680-3686. 10.1016/j.ejmech.2009.04.001PubMedCrossRef
9.
go back to reference Gauss-Müller V, Kusov YY: Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J Gen Virol 2002, 83: 2183-2192.PubMedCrossRef Gauss-Müller V, Kusov YY: Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J Gen Virol 2002, 83: 2183-2192.PubMedCrossRef
10.
go back to reference Kanda T, Gauss-Müller V, Cordes S, Tamura R, Okitsu K, Wu S, Nakamoto S, Fujiwara K, Imazeki F, Yokosuka O: Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein. J Viral Hepat 2010, 17: 618-623.PubMed Kanda T, Gauss-Müller V, Cordes S, Tamura R, Okitsu K, Wu S, Nakamoto S, Fujiwara K, Imazeki F, Yokosuka O: Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein. J Viral Hepat 2010, 17: 618-623.PubMed
11.
go back to reference Kanda T, Kusov Y, Yokosuka O, Gauss-Müller V: Interference of hepatitis A virus replication by small interfering RNAs. Biochem Biophys Res Commun 2004, 318: 341-345. 10.1016/j.bbrc.2004.03.194PubMedCrossRef Kanda T, Kusov Y, Yokosuka O, Gauss-Müller V: Interference of hepatitis A virus replication by small interfering RNAs. Biochem Biophys Res Commun 2004, 318: 341-345. 10.1016/j.bbrc.2004.03.194PubMedCrossRef
12.
go back to reference Robertson BH, Jansen RW, Khanna B, Totsuka A, Nainan OV, Siegl G, Widell A, Margolis HS, Isomura S, Ito K, Ishizu T, Moritsugu Y, Lemon SM: Genetic relatedness of hepatitis A strains recovered from different geographical regions. J Gen Virol 1992, 73: 1365-1377. 10.1099/0022-1317-73-6-1365PubMedCrossRef Robertson BH, Jansen RW, Khanna B, Totsuka A, Nainan OV, Siegl G, Widell A, Margolis HS, Isomura S, Ito K, Ishizu T, Moritsugu Y, Lemon SM: Genetic relatedness of hepatitis A strains recovered from different geographical regions. J Gen Virol 1992, 73: 1365-1377. 10.1099/0022-1317-73-6-1365PubMedCrossRef
13.
go back to reference Totsuka A, Moritsugu Y: Hepatitis A vaccine development in Japan. In Viral Hepatitis and Liver Disease. Edited by: Nishioka K, Suzuki H, Mishiro S. Tokyo: Springer-Verlag; 1994:509-513.CrossRef Totsuka A, Moritsugu Y: Hepatitis A vaccine development in Japan. In Viral Hepatitis and Liver Disease. Edited by: Nishioka K, Suzuki H, Mishiro S. Tokyo: Springer-Verlag; 1994:509-513.CrossRef
14.
go back to reference Kiyohara T, Totsuka A, Yoneyama T, Ishii K, Ito T, Wakita T: Characterization of anti-idotypic antibodies mimicking antibody- and receptor-binding sites on hepatitis A virus. Arch Virol 2009, 154: 1263-1269. 10.1007/s00705-009-0433-6PubMedCrossRef Kiyohara T, Totsuka A, Yoneyama T, Ishii K, Ito T, Wakita T: Characterization of anti-idotypic antibodies mimicking antibody- and receptor-binding sites on hepatitis A virus. Arch Virol 2009, 154: 1263-1269. 10.1007/s00705-009-0433-6PubMedCrossRef
15.
go back to reference Kanda T, Steele R, Ray R, Ray RB: Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes. J Virol 2007, 81: 12375-12381. 10.1128/JVI.01695-07PubMedPubMedCentralCrossRef Kanda T, Steele R, Ray R, Ray RB: Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes. J Virol 2007, 81: 12375-12381. 10.1128/JVI.01695-07PubMedPubMedCentralCrossRef
16.
go back to reference Fensterl V, Grotheer D, Berk I, Schlemminger S, Vallbracht A, Dotzauer A: Hepatitis A virus suppresses RIG-I-mediated IRF-3 activation to block induction of beta interferon. J Virol 2005, 79: 10968-10977. 10.1128/JVI.79.17.10968-10977.2005PubMedPubMedCentralCrossRef Fensterl V, Grotheer D, Berk I, Schlemminger S, Vallbracht A, Dotzauer A: Hepatitis A virus suppresses RIG-I-mediated IRF-3 activation to block induction of beta interferon. J Virol 2005, 79: 10968-10977. 10.1128/JVI.79.17.10968-10977.2005PubMedPubMedCentralCrossRef
17.
go back to reference Paulmann D, Magulski T, Schwarz R, Heitmann L, Flehming B, Vallbracht A, Dotzauer A: Hepatitis A virus protein 2B suppresses beta interferon (IFN) gene transcription by interfering with IFN regulatory factor 3 activation. J Gen Virol 2008, 89: 1593-1604. 10.1099/vir.0.83521-0PubMedCrossRef Paulmann D, Magulski T, Schwarz R, Heitmann L, Flehming B, Vallbracht A, Dotzauer A: Hepatitis A virus protein 2B suppresses beta interferon (IFN) gene transcription by interfering with IFN regulatory factor 3 activation. J Gen Virol 2008, 89: 1593-1604. 10.1099/vir.0.83521-0PubMedCrossRef
18.
go back to reference Yang Y, Liang Y, Qu L, Chen Z, Yi M, Li K, Lemon SM: Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci USA 2007, 104: 7253-7258. 10.1073/pnas.0611506104PubMedPubMedCentralCrossRef Yang Y, Liang Y, Qu L, Chen Z, Yi M, Li K, Lemon SM: Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci USA 2007, 104: 7253-7258. 10.1073/pnas.0611506104PubMedPubMedCentralCrossRef
19.
go back to reference Cady SD, Schmidt-Rohr K, Wang J, Soto CS, Degrado WF, Hong M: Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010, 463: 689-692. 10.1038/nature08722PubMedPubMedCentralCrossRef Cady SD, Schmidt-Rohr K, Wang J, Soto CS, Degrado WF, Hong M: Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010, 463: 689-692. 10.1038/nature08722PubMedPubMedCentralCrossRef
Metadata
Title
Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha
Authors
Lingli Yang
Tomoko Kiyohara
Tatsuo Kanda
Fumio Imazeki
Keiichi Fujiwara
Verena Gauss-Müller
Koji Ishii
Takaji Wakita
Osamu Yokosuka
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-212

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue